Avalyn Pharma Inc. (NASDAQ:AVLN) Receives $59.00 Average PT from Brokerages

Posted by George Bondi on Aug 19th, 2026

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $60.00.

Several equities research analysts recently commented on the company. Wall Street Zen cut Avalyn Pharma from a “hold” rating to a “sell” rating in a report on Saturday. Morgan Stanley increased their price target on Avalyn Pharma from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Thursday, August 13th. Zacks Research upgraded Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Weiss Ratings began coverage on Avalyn Pharma in a research note on Thursday, August 13th. They issued a “sell (d+)” rating on the stock. Finally, Guggenheim assumed coverage on Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 target price for the company.

View Our Latest Research Report on Avalyn Pharma

Hedge Funds Weigh In On Avalyn Pharma

A hedge fund recently bought a new position in Avalyn Pharma stock. Bank of New York Mellon Corp acquired a new position in Avalyn Pharma Inc. (NASDAQ:AVLN – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned about 0.09% of Avalyn Pharma at the end of the most recent reporting period.

Avalyn Pharma Trading Up 1.6%

Avalyn Pharma stock opened at $38.86 on Wednesday. The firm has a market cap of $1.72 billion and a PE ratio of -1.78. The company has a debt-to-equity ratio of 0.04, a quick ratio of 33.12 and a current ratio of 33.12. The firm’s 50-day moving average is $30.55. Avalyn Pharma has a 52 week low of $24.15 and a 52 week high of $40.17.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.98) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.05. Research analysts expect that Avalyn Pharma will post -3.81 earnings per share for the current fiscal year.

Avalyn Pharma Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.